The intense accumulation of PSMA radioligands in salivary glands is still not well understood. It is of concern for therapeutic applications of PSMA radioligands, as therapeutic radiation will damage these glands. A better understanding of the uptake mechanism is, therefore, crucial to allow the finding of solutions to reduce toxicity. The aim of this study was to investigate on whether or not the accumulation of PSMA-targeting radioligands in submandibular glands (SMG) can be explained with PSMA expression levels using the methods of autoradiography (ARG) and immunohistochemistry (IHC). Methods: All patients gave written informed consent for further utility of the biological material. SMG of 9 patients, pancreatic tissue of 4 patients and prostate cancer (PCA) lesions of 9 patients were analyzed. Fresh tissue specimen were analyzed by means of PSMA-IHC (using an anti-PSMA-antibody and an immunoreactivity score system - IRS) and ARG using 177Lu-PSMA-617 (with quantification of the relative signal intensity compared to a PSMA-positive standard). The SUVmax in salivary glands, pancreas and PCA tissues were quantified in 60 clinical 68Ga-PSMA-11 PET scans for recurrent disease, as well as the 9 primary tumors selected for ARG and IHC. Results: PCA tissue samples revealed a wide range of PSMA staining intensity on IHC (IRS 70–300) as well as in ARG (1.33 – 21.98%). This variability on PCA tissue could also be observed in 68Ga-PSMA-11 PET (SUVmax 4.4-16) with a significant correlation between ARG and SUVmax (P < 0.001, R2 = 0.897). On IHC, ARG and 68Ga-PSMA-11 PET, the pancreatic tissue was negative (IRS = 0, ARG = 0.1±0.05%, SUVmax of 3.1±1.1). The SMG tissue displayed only focal expression of PSMA limited to the intercalated ducts on IHC (IRS 10-15) and a minimal signal on ARG (1.3±0.9%). In contrast, all SMG showed a high 68Ga-PSMA-11 accumulation on PET scans (SUVmax 23.5±5.2). Conclusion: Our results indicate that the high accumulation of PSMA radioligands in salivary glands does not correspond to a high PSMA expression levels determined using ARG and IHC. These findings provide evidence, that the significant accumulation of PSMA radioligands in SMG is not primarily a result of PSMA-mediated uptake.
30 November 2014 in Clinical & Experimental Metastasis
Diagnosis of salivary gland neoplasms is often challenging due to their high morphological diversity and overlaps. Several recurrent molecular alterations have been described recently, which can serve as powerful diagnostic tools and potential therapeutic targets (e.g. NTRK or RET fusions). However, current sequential molecular testing can be expensive and time consuming. In order to facilitate the diagnosis of salivary gland neoplasms, we designed an all-in-one RNA-based next generation sequencing panel suitable for the detection of mutations, fusions and gene expression levels (including NR4A3) of 27 genes involved in salivary gland neoplasms. Here we present the validation of the "SalvGlandDx" panel on FFPE histological specimen including fine needle aspiration (FNA) cell block material, against the standard methods currently used at our institution. In a second part we describe selected unique cases in which the SalvGlandDx panel allowed proper diagnosis and new insights into special molecular characteristics of selected salivary gland tumors. We characterize a unique salivary gland adenocarcinoma harboring a ZCCHC7-NTRK2 fusion, a highly uncommon spindle cell and pseudoangiomatoid adenoid-cystic carcinoma with MYBL1-NFIB fusion, and a purely oncocytic mucoepidermoid carcinoma, whereas diagnosis could be made by detection of a CRTC3-MAML2 rearrangement on the cell block specimen of the FNA. Further, a rare case of a SS18-ZBTB7A rearranged low-grade adenocarcinoma previously described as potential spectrum of microsecretory adenocarcinoma, is reported. In addition, features of six cases within the spectrum of polymorphous adenocarcinoma / cribriform adenocarcinoma of salivary gland including PRKD1 p.E710D mutations and novel fusions involving PRKAR2A-PRKD1, SNX9-PRKD1 and ATL2-PRKD3, are described.
The aim of this study was to investigate the predictability of occult lymph node metastasis using maximum standardized uptake value (SUVmax) in the primary tumor on pre-treatment 18-fluorodeoxyglucose positron emission tomography FDG-PET in oral squamous cell carcinoma (OSCC) patients who were clinically node negative (cN0) before surgery. A retrospective analysis of all patients treated at the University Hospital Zurich from 2007 to 2016 for OSCC with available pre-therapeutic FDG-PET was performed. We assessed the correlation of SUVmax of the primary tumors with the presence of occult nodal disease in the neck dissection specimen (pN+). The study included a total of 71 patients. In the nodal negative group (cN0/pN0), the median SUVmax of primary tumors was 9.0 (interquartile range (IQR) 7.4–13.9), while it was 11.4 (IQR 9.9–15.7) in the occult metastatic group (cN0/pN+). The difference was statistically significant (independent samples median test, P = 0.037). In a multivariable model, the only independent predictor of occult metastatic disease for cN0 patients was a SUVmax ≥ 9.5 (P = 0.028). Further, primary tumors with SUVmax ≥ 9.5 had a significantly higher risk of local recurrence (Log rank test, P = 0.020). In conclusion, we showed that higher SUVmax (≥9.5) of the primary tumor is associated with higher occurrence of occult metastatic nodal disease and worse local survival. High SUVmax of the primary tumor may encourage clinicians towards more aggressive treatment.
In oral squamous cell carcinoma (OSCC), depth of invasion (DOI) is an important predictive, prognostic, and staging parameter. While it is known that DOI can be estimated from preoperative imaging, an analysis of measurements variations according to imaging modality and to depth of tumor itself is lacking. The aim of the study was to assess the accuracy of imaging-based estimation of DOI in relation with the tumor histological DOI. We retrospectively reviewed 121 patients with OSCC treated at University Hospital Zurich. The radiologic DOI of CT, T1-weighted, and T2-weighted MRI were compared with histological DOI. Frequency of relevant imaging artifacts was assessed as well. A total of 110 CT (90.9 %) and 90 MRI (74 %) were analyzed. Both modalities were available for 79 patients (65.3 %). The median histological depth of invasion was 9 mm (IQR 4.5-14). The median depth of invasion was 14 mm (IQR 10-20) on CT, 13 mm (IQR 8.25-18) on T1-weighted MRI, and 13 mm (IQR 9-18.75) on T2-weighted MRI. All diagnostic modalities tended towards an overestimation of the histopathologic DOI from about 5-15 %. This trend was most pronounced for thin tumors, for which both CT and MRI lead to upstaging in over 50 % of the cases. For 25 (22.7 %) patients, dental scattering on CT rendered DOI not estimable. For MRI, 18 patients (20 %) had artifacts (blooming, motion artifacts) rendering DOI not estimable. CT and MRI measurements of DOI in OSCC lead to an overestimation of histological DOI, especially in tumors with DOI<5 mm, with upstaging by imaging in over 50 % of the cases. Artifacts were present in more than 20 % of performed images.